Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Joanna Mulder

Nurse Practitioner, Psychiatric/Mental Health Valrico, FL Nurse Practitioner

NPI 1386639151 CMS profile 10982443

2553 Mason Oaks Dr, Valrico, FL 33596

Open in the dashboard

General payments

$604

25 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Joanna Mulder of Valrico, FL is reported in the CMS Open Payments database as having received $604 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $218 9
2022 General $208 5
2021 General $178 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joanna Mulder
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Joanna Mulder were reported at $0. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Joanna Mulder Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $178 $166 $54–$482 $132
2022 $208 $195 $66–$559 $149
2023 $218 $233 $82–$673 $160
2024 $0 $236 $84–$688 $164
2025 $0 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Otsuka America Pharmaceutical, Inc. $566 23 payments
  2. Indivior Inc. $39 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $604 25 payments
Products named General payments · program years 2021–2023
  1. ABILIFY MAINTENA $386 18 payments
  2. REXULTI $361 17 payments
  3. PERSERIS $39 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 172 drugs

Part D claims

17,951

Median for Nurse Practitioner: 389

Drug cost

$1,807,050

Median for Nurse Practitioner: $21,885

Branded share of claims

11.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 196 $573,573
Invega Sustenna Paliperidone Palmitate Brand 112 $382,697
Rexulti Brexpiprazole Brand 113 $164,374
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 12 $55,572
Aripiprazole Generic 433 $48,148
Perseris Risperidone Brand 15 $46,288
Jardiance Empagliflozin Brand 46 $28,751
Vraylar Cariprazine Hcl Brand 18 $27,858
Quetiapine Fumarate Generic 1,023 $23,714
Eliquis Apixaban Brand 35 $21,996

The 10 drugs with the highest cost, of 172 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$91,459

Of which drugs: $756

Medicare patients

205

Average age 50

Services billed

2,184

68 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Depression 65%
Diabetes 26%
Arthritis 20%
Chronic kidney disease 16%
Alzheimer's or dementia 16%
COPD 13%
Heart failure 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aripiprazole, extended release, 1 mg J0401 Office 14 67 $283
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 15 15 $147

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record